DK1651642T3 - PNA-monomer og prækursor - Google Patents
PNA-monomer og prækursorInfo
- Publication number
- DK1651642T3 DK1651642T3 DK04726242T DK04726242T DK1651642T3 DK 1651642 T3 DK1651642 T3 DK 1651642T3 DK 04726242 T DK04726242 T DK 04726242T DK 04726242 T DK04726242 T DK 04726242T DK 1651642 T3 DK1651642 T3 DK 1651642T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- halogenated
- alkoxy
- alkyl
- oligomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49079203P | 2003-07-28 | 2003-07-28 | |
PCT/IB2004/050406 WO2005009998A1 (en) | 2003-07-28 | 2004-04-07 | Pna monomer and precursor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1651642T3 true DK1651642T3 (da) | 2009-12-14 |
Family
ID=34102993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04726242T DK1651642T3 (da) | 2003-07-28 | 2004-04-07 | PNA-monomer og prækursor |
Country Status (9)
Country | Link |
---|---|
US (1) | US7211668B2 (ja) |
EP (1) | EP1651642B1 (ja) |
JP (1) | JP4441535B2 (ja) |
KR (2) | KR20070040420A (ja) |
CN (1) | CN1829714B (ja) |
AT (1) | ATE447569T1 (ja) |
DE (1) | DE602004023951D1 (ja) |
DK (1) | DK1651642T3 (ja) |
WO (1) | WO2005009998A1 (ja) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
WO2009032901A1 (en) * | 2007-09-04 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biosensors and related methods |
KR101072899B1 (ko) * | 2008-01-21 | 2011-10-17 | 주식회사 파나진 | 아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용 |
KR101360037B1 (ko) * | 2008-12-02 | 2014-02-07 | 현대자동차주식회사 | 차량용 lng 연료 탱크 |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US8697858B2 (en) | 2009-11-13 | 2014-04-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US20120309684A1 (en) | 2009-11-30 | 2012-12-06 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
EP2563381B1 (en) | 2010-04-27 | 2017-08-09 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
EP2563911B1 (en) | 2010-04-28 | 2021-07-21 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
EP2566496B1 (en) | 2010-05-03 | 2018-02-28 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
AU2011248101B2 (en) | 2010-05-04 | 2016-10-20 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
EP3023496B1 (en) | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
AU2011252990B2 (en) | 2010-05-14 | 2017-04-20 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
AU2011256366C1 (en) | 2010-05-17 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
JP6046607B2 (ja) | 2010-05-27 | 2016-12-21 | エータイアー ファーマ, インコーポレイテッド | グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
JP6116479B2 (ja) | 2010-07-12 | 2017-04-19 | エータイアー ファーマ, インコーポレイテッド | グリシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
CA2839593A1 (en) | 2011-07-15 | 2013-01-24 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
JP6132848B2 (ja) | 2011-12-08 | 2017-05-31 | サレプタ セラピューティクス, インコーポレイテッド | ヒトlmnaを標的とするオリゴヌクレオチド類似体 |
CN104603118B (zh) * | 2012-05-31 | 2017-10-03 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物 |
US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
CN103145714A (zh) * | 2013-03-13 | 2013-06-12 | 苏州维泰生物技术有限公司 | 公斤级合成pna的方法 |
US20150197534A1 (en) | 2013-09-05 | 2015-07-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
EP3221445B1 (en) | 2014-11-20 | 2021-07-14 | The Regents of The University of California | Compositions and methods related to hematologic recovery |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
JP6873052B2 (ja) | 2015-06-01 | 2021-05-19 | サレプタ セラピューティクス,インコーポレイテッド | Vii型コラーゲンにおけるアンチセンス誘導エクソン排除 |
CA2995995A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
KR20180071362A (ko) | 2015-11-16 | 2018-06-27 | 올릭스 주식회사 | MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료 |
CA3022874A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1 |
US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
AU2017258642B2 (en) | 2016-04-29 | 2023-08-31 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human LMNA |
US20190262375A1 (en) | 2016-06-30 | 2019-08-29 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
PT3554553T (pt) | 2016-12-19 | 2022-08-04 | Sarepta Therapeutics Inc | Conjugados oligoméricos de salto de exão para a distrofia muscular |
CA3046801A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP3554552B1 (en) | 2016-12-19 | 2022-08-17 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
US10538808B2 (en) | 2017-05-26 | 2020-01-21 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
EP3687577A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
US20200248178A1 (en) | 2017-09-28 | 2020-08-06 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
US20200254002A1 (en) | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
EP3697910A4 (en) | 2017-10-18 | 2021-07-14 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
US11273137B2 (en) | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
AU2019397461A1 (en) | 2018-12-13 | 2021-07-29 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
AU2020237225A1 (en) | 2019-03-12 | 2021-10-14 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
US20220193246A1 (en) | 2019-04-18 | 2022-06-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
WO2020252257A1 (en) | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
KR20210082091A (ko) | 2019-12-24 | 2021-07-02 | 주식회사 시선바이오머티리얼스 | 개질된 감마탄소 골격 화합물 및 이의 제조방법 |
KR102403904B1 (ko) | 2019-12-24 | 2022-06-02 | 주식회사 시선바이오머티리얼스 | 용액공정상 pna 올리고머의 제조방법 |
KR20230004456A (ko) | 2020-03-04 | 2023-01-06 | 리제너론 파아마슈티컬스, 인크. | 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물 |
EP4157264A4 (en) | 2020-05-27 | 2024-06-19 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TRANSDIFFERENTIATION OF CELLS |
WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
CA3195231A1 (en) | 2020-09-16 | 2022-03-24 | President And Fellows Of Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
AU2022358322A1 (en) | 2021-09-30 | 2024-05-16 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
EP4419680A1 (en) | 2021-10-22 | 2024-08-28 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2023091704A1 (en) | 2021-11-18 | 2023-05-25 | Circularis Biotechnologies, Inc. | Compositions and methods for production of circular nucleic acid molecules |
WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
US20240182561A1 (en) | 2022-11-04 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024104914A1 (en) | 2022-11-14 | 2024-05-23 | BioNTech SE | Rna capping efficiency assay |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635956A (en) * | 1968-03-01 | 1972-01-18 | Squibb & Sons Inc | Benzothiazines related compounds derivatives and salts thereof |
IT1059127B (it) * | 1976-04-15 | 1982-05-31 | Montedison Spa | Eteri e tioeteri benzilici o feni lici a catena alifatica lineare con terminale alogenato ad attivi ta ormonica giovanile e acaric/da |
US5435939A (en) * | 1993-07-07 | 1995-07-25 | Isp Investments Inc. | Stable emulsifiable gel matrix and aqueous macroemulsion prepared therefrom |
US5539083A (en) * | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
JP2002520008A (ja) | 1998-07-09 | 2002-07-09 | バイオセプト インコーポレイテッド | Dna配列ハイブリッド形成を最適化するための改良されたペプチド核酸汎用ライブラリーの使用法 |
CN100344623C (zh) * | 2001-05-15 | 2007-10-24 | 三井化学株式会社 | 丙烯酸酯化合物及其用途 |
KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
-
2004
- 2004-04-06 US US10/819,769 patent/US7211668B2/en active Active
- 2004-04-07 EP EP04726242A patent/EP1651642B1/en not_active Expired - Lifetime
- 2004-04-07 KR KR1020077006779A patent/KR20070040420A/ko not_active Application Discontinuation
- 2004-04-07 DK DK04726242T patent/DK1651642T3/da active
- 2004-04-07 AT AT04726242T patent/ATE447569T1/de not_active IP Right Cessation
- 2004-04-07 CN CN2004800220716A patent/CN1829714B/zh not_active Expired - Lifetime
- 2004-04-07 KR KR1020067002202A patent/KR100752552B1/ko active IP Right Grant
- 2004-04-07 DE DE602004023951T patent/DE602004023951D1/de not_active Expired - Lifetime
- 2004-04-07 JP JP2006521712A patent/JP4441535B2/ja not_active Expired - Lifetime
- 2004-04-07 WO PCT/IB2004/050406 patent/WO2005009998A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR100752552B1 (ko) | 2007-08-29 |
US20050026930A1 (en) | 2005-02-03 |
WO2005009998A1 (en) | 2005-02-03 |
KR20060037415A (ko) | 2006-05-03 |
CN1829714A (zh) | 2006-09-06 |
US7211668B2 (en) | 2007-05-01 |
JP4441535B2 (ja) | 2010-03-31 |
EP1651642B1 (en) | 2009-11-04 |
KR20070040420A (ko) | 2007-04-16 |
ATE447569T1 (de) | 2009-11-15 |
CN1829714B (zh) | 2012-05-30 |
DE602004023951D1 (de) | 2009-12-17 |
EP1651642A4 (en) | 2006-11-29 |
JP2007500184A (ja) | 2007-01-11 |
EP1651642A1 (en) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1651642T3 (da) | PNA-monomer og prækursor | |
DK1501812T3 (da) | PNA-monomer og prækursor | |
DE60328866D1 (de) | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen | |
CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
TWI266761B (en) | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
BR0211078A (pt) | Compostos, processo papa a preparação e uso dos mesmos, composições herbicidas, e, método para o controle de ervas daninhas em áreas cultivadas | |
CY1111349T1 (el) | Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου | |
HK1048465A1 (en) | Aminobenzophenones as inhibitors of il-1B and tnf-a. | |
ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
ATE277891T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
HUP0302193A2 (hu) | 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
DK0618193T3 (da) | Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer | |
IN2012DN02546A (ja) | ||
WO2004087647A3 (fr) | Derives de quinoleines-4-substituees avec une activite antimicrobienne | |
DK1408953T3 (da) | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom | |
JP2002501043A5 (ja) | ||
EP1375496A4 (en) | N-ARYL SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICAMENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | |
DK1325923T3 (da) | Cephem-forbindelser og ESBL-detekterende reagenser indeholdende disse | |
WO2005016916A3 (fr) | Quinolines substituées comme antimicrobiens | |
HRP20090012T3 (en) | 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof | |
DE602005001704D1 (de) | Verfahren zur herstellung von alkoxycarbonylmethoxy-cyclopentanen | |
DE602004009306D1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern | |
DE50004320D1 (de) | Stabilisierte zusammensetzungen von o- und n-vinylverbindungen und verwendung von ammoniumsalzen als stabilisierungsmittel | |
TH62866A (th) | ไดเอริลเปปไตด์เป็นสารยับยั้ง ns8- ซิรีนโปรดิเอสของไวรัสตับอักเสบ c |